jeudi 4 avril 2019

Onco Actu du 4 avril 2019


1. BIOLOGIE



New role for a driver of metastatic cancers [Salk Institute]











1.4 BIOLOGIE - TECHNOS



China's Selling Genetically-Modified Mice for $17,000 a Pair [Bloomberg]











2. ETIOLOGIE



Family colon cancer risk similar for siblings and half siblings [Reuters]











Some Cancers Become Contagious [The Scientist]











2.12 ETIOLOGIE - UV



You Missed A Spot! Patchy Sunscreen Application Leaves Skin Vulnerable To Cancer [NPR]











3.1.1 PRÉVENTION - TABAC - E-CIGS



U.S. FDA warns of potential seizure risk in some users of e-cigarettes [Reuters]











Statement from FDA Commissioner Scott Gottlieb, M.D., and Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D., on FDA’s ongoing scientific investigation of potential safety issue related to seizures reported following e-cigarette use, particularly in youth and young adults [FDA]










FDA investigates reports of seizures after vaping [CNN]











3.3 PRÉVENTION - VACCINS



HPV vaccine linked to 'dramatic' cervical disease drop [BBC News]











The remarkable impact of bivalent HPV vaccine in Scotland [BMJ]










4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC



Pancreatic Cancer Biomarker Signature Uncovered by Genome-Wide Functional Variant Screen [Genome Web]











4.10 DÉP., DIAG. & PRONO. - FDA, EMA, NICE,...



FDA Starts A Discussion About How To Regulate Artificial Intelligence / Machine Learning Software As A Medical Device [FDA Law Blog]











4.12 BIOPSIES LIQUIDES



Using blood, saliva, urine to detect cancer: Scientists' 'holy grail' [CNN]











4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS



Screening also prevents rare types of cervical cancer [Karolinska Institutet]











4.9 DÉP., DIAG. & PRONO. - SEIN



Older Women Benefit Significantly When Screened with 3-D Mammography [RSNA]











Helen Salisbury: Should I persuade patients to have mammograms? [BMJ]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Editas, BlueRock team up to develop off-the-shelf engineered cell therapies [Fierce Biotech]











5.12.4 IMMUNOTHÉRAPIES - ESSAIS



Despite research boom, few immunotherapy studies targeting pancreatic cancer [Biopharma Dive]











5.2 PHARMA



After falling short on prelim OS data, EMA tells Aveo it wants to see something better on its long suffering tivo this summer — or else [EndPoints]











5.2.3 PHARMA - ÉCONOMIE



Sorrento sues Soon-Shiong over 'catch-and-kill' of its cancer drug, a potential Abraxane rival [Fierce Biotech]











Biotech billionaire faces accusations of fraud for $1.3B ‘catch-and-kill’ cancer drug deal [EndPoints]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer [Pfizer]











5.4 TRAITEMENTS - ECONOMIE



Advanced breast cancer drug combo approved for NHS in England [Cancer Research UK]











5.9 AACR



AACR 2019 Roundup: Notes from a Weekend of Early Stage Cancer Results [Xconomy]










5.9.12 AACR - BIOPSIES LIQUIDES



AACR 2019 – Foundation Medicine sets the scene for liquid biopsy approval [Vantage]










5.9.4 AACR - POUMON



AACR: BMS, clinging to Opdivo's lung cancer share, highlights long-term data [Fierce Pharma]











5.9.5 AACR - CAR-T



AACR Annual Meeting 2019: Promising Data from CAR T-cell Clinical Trials for Advanced Solid Tumors [Cancer Research Catalyst]











5.9.7 AACR - DIVERS



Project GENIE Used to Explore Impact of Rare Cancer Mutations on Treatment Response [Genome Web]











6. LUTTE CONTRE LES CANCERS



Report: Application of Cancer Reducing Strategies in the U.S. is Suboptimal [ACS]










6.6 PUBLICATIONS



‘Predatory’ Scientific Publisher Is Hit With a $50 Million Judgment [NY Times]











6.7.1 IA/BIOINFORMATIQUE



Artificial intelligence helps to better assess treatment response of brain tumors [DKFZ]











How IBM Watson Overpromised and Underdelivered on AI Health Care [IEEE Spectrum]